These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33836067)

  • 21. SARS-CoV-2 Seroprevalence Among Healthcare Workers by Job Function and Work Location in a New York Inner-City Hospital.
    Purswani MU; Bucciarelli J; Tiburcio J; Yagudayev SM; Connell GH; Omidiran AA; Hannaway L; Zeana C; Healy M; Yu G; Reich D
    J Hosp Med; 2021 May; 16(5):282-289. PubMed ID: 33929948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The seroprevalence of SARS-CoV-2 in a rural southwest community.
    Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
    J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of socio-economic disparities in the relative success and persistence of SARS-CoV-2 variants in New York City in early 2021.
    Vasylyeva TI; Havens JL; Wang JC; Luoma E; Hassler GW; Amin H; Di Lonardo S; Taki F; Omoregie E; Hughes S; Wertheim JO
    PLoS Pathog; 2024 Jun; 20(6):e1012288. PubMed ID: 38900824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among unvaccinated children of Chandigarh, Northwest India, in a household-based paediatric serosurvey post-second wave of pandemic (June to July 2021).
    Ghosh A; Goyal K; Singh R; Lakshmi PVM; Kaur R; Kumar V; Muralidharan J; Puri GD; Ram J; Singh MP
    Public Health; 2023 Dec; 225():160-167. PubMed ID: 37931485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Social Vulnerability and Rurality Associated With Higher Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection-Induced Seroprevalence: A Nationwide Blood Donor Study-United States, July 2020-June 2021.
    Li Z; Lewis B; Berney K; Hallisey E; Williams AM; Whiteman A; Rivera-González LO; Clarke KEN; Clayton HB; Tincher T; Opsomer JD; Busch MP; Gundlapalli AV; Jones JM
    Clin Infect Dis; 2022 Aug; 75(1):e133-e143. PubMed ID: 35137014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
    Yang W; Kandula S; Huynh M; Greene SK; Van Wye G; Li W; Chan HT; McGibbon E; Yeung A; Olson D; Fine A; Shaman J
    Lancet Infect Dis; 2021 Feb; 21(2):203-212. PubMed ID: 33091374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys.
    Kshatri JS; Bhattacharya D; Praharaj I; Mansingh A; Parai D; Kanungo S; Palo SK; Giri S; Pattnaik M; Barik SR; Dash GC; Choudhary HR; Turuk J; Mandal NN; Pati S
    Epidemiol Infect; 2021 Apr; 149():e139. PubMed ID: 33902776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.
    Yoshiyama T; Saito Y; Masuda K; Nakanishi Y; Kido Y; Uchimura K; Mitarai S; Suzuki T; Nakagama Y; Kubota H; Satomi M; Uchikoba S; Ohnishi M; Wakita T; Kato S; Kato K
    Emerg Infect Dis; 2021 Feb; 27(2):628-631. PubMed ID: 33496235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned.
    Poljak M; Oštrbenk Valenčak A; Štrumbelj E; Maver Vodičar P; Vehovar V; Resman Rus K; Korva M; Knap N; Seme K; Petrovec M; Zupan B; Demšar J; Kurdija S; Avšič Županc T
    Clin Microbiol Infect; 2021 Jul; 27(7):1039.e1-1039.e7. PubMed ID: 33838303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.
    Kataria Y; Cole M; Duffy E; de la Cena K; Schechter-Perkins EM; Bouton TC; Werler MM; Pierre C; Ragan EJ; Weber SE; Jacobson KR; Andry C
    Sci Rep; 2021 May; 11(1):9694. PubMed ID: 33958668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.
    Maltezou HC; Krumbholz B; Mavrouli M; Tseroni M; Gamaletsou MN; Botsa E; Anastassopoulou C; Gikas A; Fournarakou E; Kavieri M; Koureli A; Mandilara D; Marinopoulou A; Theodorikakou A; Tsiahris P; Zarzali A; Pournaras S; Lourida A; Elefsiniotis I; Vrioni G; Sipsas NV; Tsakris A
    J Med Virol; 2022 Apr; 94(4):1465-1472. PubMed ID: 34812522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of COVID-19 Virus Infection in Semnan province.
    Jandaghi E; Hemati M; Mohammadlou M; Jandaghi J; Mirmohammadkhani M; Danaei N; Kokhaei P
    Iran J Immunol; 2021 Mar; 18(1):74-81. PubMed ID: 33787516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand.
    Carlton LH; Chen T; Whitcombe AL; McGregor R; Scheurich G; Sheen CR; Dickson JM; Bullen C; Chiang A; Exeter DJ; Paynter J; Baker MG; Charlewood R; Moreland NJ
    Epidemiol Infect; 2021 Jul; 149():e173. PubMed ID: 34668464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.
    Fofana MO; Nery N; Aguilar Ticona JP; de Andrade Belitardo EMM; Victoriano R; Anjos RO; Portilho MM; de Santana MC; Dos Santos LL; de Oliveira D; Cruz JS; Muenker MC; Khouri R; Wunder EA; Hitchings MDT; Johnson O; Reis MG; Ribeiro GS; Cummings DAT; Costa F; Ko AI
    PLoS Med; 2022 Sep; 19(9):e1004093. PubMed ID: 36074784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave.
    Barallat J; Fernández-Rivas G; Quirant-Sánchez B; González V; Doladé M; Martinez-Caceres E; Piña M; Matllo J; Estrada O; Blanco I
    PLoS One; 2020; 15(12):e0244348. PubMed ID: 33370363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India.
    Selvaraju S; Kumar MS; Thangaraj JWV; Bhatnagar T; Saravanakumar V; Kumar CPG; Sekar K; Ilayaperumal E; Sabarinathan R; Jagadeesan M; Hemalatha MS; Murhekar MV;
    Emerg Infect Dis; 2021 Feb; 27(2):586-589. PubMed ID: 33496222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reply: Seroprevalence of SARS-CoV-2 After the Largest Initial Epidemic Wave in the United States: Findings from New York City, May 13-July 21, 2020.
    Allan-Blitz LT; Klausner JD
    J Infect Dis; 2021 Aug; 224(3):556-557. PubMed ID: 33963752
    [No Abstract]   [Full Text] [Related]  

  • 38. Coronavirus Disease 2019 Exposure in Surgeons and Anesthesiologists at a New York City Specialty Hospital: A Cross-Sectional Study of Symptoms and SARS-CoV-2 Antibody Status.
    Soffin EM; Reisener MJ; Padgett DE; Kelly BT; Sama AA; Zhu J; Salzmann SN; Chiapparelli E; Okano I; Oezel L; Miller AO; Cammisa FP; Girardi FP; Hughes AP
    J Occup Environ Med; 2021 Jun; 63(6):521-527. PubMed ID: 34048384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [SARS-CoV-2 Seroprevalence Among Healthcare Workers: Retrospective Analysis of the Data From A University Hospital in Turkey].
    Özdemir A; Demir Çuha M; Telli Dizman G; Alp A; Metan G; Şener B
    Mikrobiyol Bul; 2021 Apr; 55(2):223-232. PubMed ID: 33882653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.